InflammX Clinical Candidates and Indications
Therapeutic target and biological effect
InflammX has developed two distinct Clinical Candidates based upon robust and repeatable clinical and pre-clinical data.
Xiflam™
Xentry-Gap19
The InflammX therapeutic target is the Connexin43 protein, a component of the most ubiquitous connexin hemichannel that under pathological conditions is over-expressed and opens creating a pathological membrane pore that perpetuates a cycle of inflammation through the activated inflammasome pathway. By blocking aberrant opening of the connexin hemichannel, the chronic cycle of inflammation is shut down. Pathology related to a continuing cycle of inflammation includes loss of vascular integrity, vascular leakage, edema, microvascular dropout, ischemia, pathological neovascularisation and fibrosis. Shutting down the inflammation and inflammatory cytokine production, provides the damaged tissues the opportunity to repair and regenerate in an environment of physiological homeostasis.
